Save the Date: Monday, October 20, 2025 , when our Research in Action Awards return this fall! We'll honor some of the most brilliant activists, scientists, and leaders in the fight to end HIV, tuberculosis (TB), and hepatitis C (HCV). And until July 1, get tickets at our special-early bird rate!
Treatment Action Group (TAG) opposes in the strongest possible terms the suspension of at least 22 TB research awards by the National Institutes of Health (NIH) following a May 2025 White House executive order banning “gain-of-function” research.
The World Health Organization (WHO) guidelines for diagnosing TB have evolved along with available technologies and tools that are increasingly accurate, simple, and efficient at detecting TB and resistance to a wider range of TB drugs.
TAG's Senior TB Project Associate, Erin McConnell, created this 'zine about TAG for Pride 2025. It's about fighting back, and goes over current threats, action items, and action steps on how to show up.
Join us for a community webinar to break down the latest World Health Organization (WHO) guidelines and explore the most effective tools for diagnosing TB and drug resistance.
On June 5, 2025, TAG and WHO cohosted a webinar orienting people to long-acting injectables for TB treatment and prevention. Long-acting Injectables (LAIs) have the potential to revolutionize treatment for TB and other infectious diseases.
These are the remarks delivered by Mike Frick, TAG’s TB co-director, who was speaking as a civil society representative, at the 3rd meeting of the WHO Director-General’s TB Vaccine Accelerator Council on May 20, 2025 in Geneva, Switzerland.
Lifesaving scientific research on prevention, testing, treatment and care for people living with HIV and tuberculosis (TB) in South Africa is under serious threat due to funding suspensions and grant terminations from the United States (US) government.
Developed by TAG, Médecins Sans Frontières, and the South African Medical Research Council, this issue brief provides information about TB and HIV clinical trials and research programs impacted by U.S. government funding disruptions...